# A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib

Source: https://onco.cc/trials/nct03744715/  
OnCo record `nct03744715` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Poziotinib in Breast cancer, run by Spectrum Pharmaceuticals, Inc, recorded as terminated on the registry.

## Summary

A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib is a phase 2 interventional study registered as NCT03744715 by Spectrum Pharmaceuticals, Inc, with 7 participants recorded, started 2018-10-11 and due to reach its primary completion in 2023-03-03. Interventions recorded: Poziotinib. Conditions recorded: NSCLC, Breast Cancer.

Linked to the drug Poziotinib because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03744715
- Phase: 2
- Setting: An Open-Label Extension Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib
- Sponsor: Spectrum Pharmaceuticals, Inc
- Enrolled: 7

## Sources

- ClinicalTrials.gov NCT03744715: https://clinicaltrials.gov/study/NCT03744715

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Poziotinib](https://onco.cc/drugs/poziotinib/)
- companies: [Spectrum Pharmaceuticals](https://onco.cc/companies/spectrum-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct03744715.json